Search
Veru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
Categories: Experimental Unapproved Treatments for COVID-19Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalThe human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). … Synagis is a composite of human (95%) and murine (5%) antibody sequences.
Categories: Antiinfectives for Systemic UseProducts: Synagis 100mg/ml solution for Injection, SYNAGIS SOLUTION FOR INJECTION 100MG/MLZytron
go.drugbank.com/drugs/DB11768ApprovedWithdrawnDMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota. … Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic).
Voriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigationalVoriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. … The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: VORICONAZOL AL 50MG, VORICONAZOL AL 200 MGMetipranolol
go.drugbank.com/drugs/DB01214ApprovedWithdrawnA beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Enpatoran
go.drugbank.com/drugs/DB16501InvestigationalAdditionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis … It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327).
Categories: Experimental Unapproved Treatments for COVID-19Bumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis
Amrinone
go.drugbank.com/drugs/DB01427ApprovedWithdrawnAmrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
Categories: Compounds used in a research, industrial, or household settingRESP301
go.drugbank.com/drugs/DB16497InvestigationalAdditionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in
Categories: Experimental Unapproved Treatments for COVID-19LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union. … [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage.
Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DS